Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA to amend Dendreon’s SPA for Provenge Phase III study
In addition, the FDA has reconfirmed that they would accept a positive interim or final analysis from the Impact (immunotherapy for prostate adenocarcinoma treatment) trial to amend the
In addition, the FDA has reconfirmed that they would accept a positive interim or final analysis from the Impact (immunotherapy for prostate adenocarcinoma treatment) trial to amend the
The trial evaluated the efficacy, safety and tolerability of two doses of CRx-191 compared to placebo in subjects with psoriasis. In this trial, the high dose of CRx-191
Under the terms of the agreement, Bayer HealthCare will have a non-exclusive research licence for the use of BioInvent’s proprietary n-CoDeR library for the discovery of human monoclonal
White Cross will focus their marketing efforts on the over 70,000 German speaking dentists practicing in Europe. To help educate German-speaking dentists on the use of PreViser technology,
Global Medical Consulting Services (GMCS) has increased its services to offer full management to both Western and Asian pharmaceutical, biotech and medical device companies intending to conduct clinical
This investigator-sponsored Phase I clinical study was designed to assess safety, tolerability and clinical responses against metastatic melanoma after administration of plasmid-based IL-12 delivered intratumorally by Inovio’s electroporation
Adverse event reports associated with Tussionex have included life-threatening side effects and deaths in patients, including children. The reports show that Tussionex is sometimes prescribed or given to
The data safety monitoring board (DSMB) meeting reviewed 28-week data for approximately 50% of the patients in the study. The DSMB noted in their report very few dropouts
Upon completion of the research studies, the agreement provides Cerner an option for exclusive licensing of University of New Mexico Health Sciences Center’s (UNMHSC) technology for clinical and
Oramed plans to start Phase IIA clinical trials in Israel in the second quarter of 2008. The Phase IIA study is designed to evaluate the safety and efficacy